Dynamical properties of a minimally parameterized mathematical model for metronomic chemotherapy

Journal of Mathematical Biology

Volumn 72, Issue 5, 2016, Pages 1255-1280

  Schättler, Heinz ^a   Ledzewicz, Urszula ^b   Amini, Behrooz ^b  

^a WASHINGTON UNIVERSITY   (United States)

^b SOUTHERN ILLINOIS UNIVERSITY EDWARDSVILLE   (United States)

Author keywords

Dynamical system; Metronomic chemotherapy; Modeling of cancer treatment; Saddle node bifurcations; Tumor microenvironment

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; IMMUNOLOGICAL ADJUVANT;

BIOLOGICAL MODEL; COMPUTER SIMULATION; DRUG EFFECTS; HUMAN; IMMUNOLOGY; MATHEMATICAL PHENOMENA; METRONOMIC DRUG ADMINISTRATION; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; TUMOR MICROENVIRONMENT; VASCULARIZATION;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, METRONOMIC; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; COMPUTER SIMULATION; HUMANS; MATHEMATICAL CONCEPTS; MODELS, BIOLOGICAL; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; TUMOR MICROENVIRONMENT;

EID: 84959213890     PISSN: 03036812     EISSN: 14321416     Source Type: Journal    
DOI: 10.1007/s00285-015-0907-y     Document Type: Article

References (50)

1. André N, Padovani L, Pasquier E (2011) Metronomic scheduling of anticancer treatment: the next generation of multitarget therapy? Future Oncol 7(3):385–394
2. Benzekry S, Hahnfeldt P (2013) Maximum tolerated dose versus metronomic scheduling in the treatment of metastatic cancers. J Theor Biol 335:235–244
3. Benzekry S, André N, Benabdallah A, Ciccolini J, Faivre C, Hubert F, Barbolosi D (2012) Modeling the impact of anticancer agents on metastatic spreading. Math Model Nat Phenom 7(1):306–336. doi:10.1051/mmnp/20127114
4. Bocci G, Nicolaou K, Kerbel RS (2002) Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Res 62:6938–6943
5. Browder T, Butterfield CE, Kräling BM, Shi B, Marshall B, O’Reilly MS, Folkman J (2000) Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60:1878–1886
6. d’Onofrio A (2005) A general framework for modelling tumor-immune system competition and immunotherapy: mathematical analysis and biomedical inferences. Physica D 208:202–235
7. d’Onofrio A (2006) Tumor-immune system interaction: modeling the tumor-stimulated proliferation of effectors and immunotherapy. Math Models Methods Appl Sci 16:1375–1401
8. d’Onofrio A (2009) Fractal growth of tumors and other cellular populations: linking the mechanistic to the phenomenological modeling and vice versa. Chaos Solitons Fractals 41:875–880
9. d’Onofrio A, Gandolfi A (2004) Tumour eradication by antiangiogenic therapy: analysis and extensions of the model by Hahnfeldt et al. Math. Biosci. 191:159–184
10. d’Onofrio A, Gandolfi A (2009) A family of models of angiogenesis and anti-angiogenesis anti-cancer therapy. Math Med Biol 26:63–95. doi:10.1093/imammb/dqn024
11. d’Onofrio A, Ledzewicz U, Maurer H, Schättler H (2009) On optimal delivery of combination therapy for tumors. Math Biosci 222:13–26. doi:10.1016/j.mbs.2009.08.004
12. d’Onofrio A, Ledzewicz U, Schättler H (2012) On the dynamics of tumor-immune system interactions and combined chemo- and immunotherapy. In: d’Onofrio A, Cerrai P, Gandolfi A (eds) New challenges for cancer systems biomedicine. SIMAI Springer Series, vol 1. Springer, Milan, pp 249–266
13. Davis S, Yancopoulos GD (1999) The angiopoietins: Yin and Yang in angiogenesis. Curr Top Microbiol Immunol 237:173–185
14. de Pillis LG, Radunskaya A, Wiseman CL (2005) A validated mathematical model of cell-mediated immune response to tumor growth. Cancer Res 65:7950–7958
15. de Pillis LG, Mallet DG, Radunskaya AE (2006) Spatial tumor-immune modeling, special issue devoted to cancer and medical treatment modelling. J Comput Math Methods Med 7:159–176
16. de Vladar HP, González JA (2004) Dynamic response of cancer under the influence of immunological activity and therapy. J Theor Biol 227:335–348
17. Delitalia M, Lorenzi T (2013) Recognition and learning in a mathematical model for immune response against cancer. Discret Top Contin Dyn Syst Ser B 18:891–914
18. Eftimie R, Bramson JL, Earn DJD (2010) Interactions between the immune system and cancer: a brief review of non-spatial mathematical models. Bull Math Biol 73(1):2–32
19. Ergun A, Camphausen K, Wein LM (2003) Optimal scheduling of radiotherapy and angiogenic inhibitors. Bull Math Biol 65:407–424
20. Friedman A, Kim Y (2011) Tumor cell proliferation and migration under the influence of their microenvironment. Math Biosci Eng 8(2):371–383
21. Gatenby RA, Silva AS, Gillies RJ, Frieden BR (2009) Adaptive therapy. Cancer Res 69:4894–4903
22. Guckenheimer J, Holmes P (1983) Nonlinear oscillations, dynamical systems, and bifurcations of vector fields. Springer, New York
23. Hahnfeldt P, Panigrahy D, Folkman J, Hlatky L (1999) Tumor development under angiogenic signaling: a dynamical theory of tumor growth, treatment response, and postvascular dormancy. Cancer Res 59:4770–4775
24. Hanahan D, Bergers G, Bergsland E (2000) Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Investig 105(8):1045–1047
25. Hahnfeldt P, Folkman J, Hlatky L (2003) Minimizing long-term burden: the logic for metronomic chemotherapeutic dosing and its angiogenic basis. J Theor Biol 220:545–554
26. Kamen B, Rubin E, Aisner J, Glatstein E (2000) High-time chemotherapy or high time for low dose? J Clin Oncol 18:2935–2937 (editorial)
27. Kim Y, Friedman A (2010) Interaction of tumor with its microenvironment: a mathematical model. Bull Math Biol 72:1029–1068
28. Klement G, Baruchel S, Rak J, Man S, Clark K, Hicklin DJ, Bohlen P, Kerbel RS (2000) Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J. Clin Investig 105(8):R15–R24
29. Kuznetsov VA, Makalkin IA, Taylor MA, Perelson AS (1994) Nonlinear dynamics of immunogenic tumors: parameter estimation and global bifurcation analysis. Bull Math Biol 56:295–321
30. Lavi O, Greene JM, Levy D, Gottesman MM (2013) The role of cell density and intratumoral heterogeneity in multidrug resistance. Cancer Res 73(24):7168–7175
31. Ledzewicz U, Schättler H (2007) Anti-angiogenic therapy in cancer treatment as an optimal control problem. SIAM J Control Optim 46:1052–1079
32. Ledzewicz U, Schättler H (2014a) A review of optimal chemotherapy protocols: from MTD towards metronomic therapy. Math Model Nat Phenom 9(4):131–152. doi:10.1051/mmnp/20149409
33. Ledzewicz U, Schättler H (2014b) Tumor microenvironment and anticancer therapies: an optimal control approach. In: d’Onofrio A, Gandolfi A (eds) Mathematical oncology. Springer, Berlin
34. Ledzewicz U, Naghnaeian M, Schättler H (2012a) Optimal response to chemotherapy for a mathematical model of tumor-immune dynamics. J Math Biol 64:557–577. doi:10.1007/s00285-011-0424-6
35. Ledzewicz U, Olumoye O, Schättler H (2012b) On optimal chemotherapy with a stongly targeted agent for a model of tumor-immune system interactions with generalized logistic growth. Math Biosci Eng 10(3):787–802. doi:10.3934/mbe.2013.10.787
36. Ledzewicz U, Faraji Mosalman MS, Schättler H (2013) Optimal controls for a mathematical model of tumor-immune interactions under targeted chemotherapy with immune boost. Discret Contin Dyn Syst Ser B 18:1031–1051. doi:10.3934/dcdsb.2013.18.1031
37. Lorz A, Lorenzi T, Hochberg ME, Clairambault J, Perthame B (2013) Populational adaptive evolution, chemotherapeutic resistance and multiple anti-cancer therapies. ESAIM Math Model Numer Anal 47:377–399. doi:10.1051/m2an/2012031
38. Norton L, Simon R (1977) Tumor size, sensitivity to therapy, and design of treatment schedules. Cancer Treat Rep 61:1307–1317
39. Norton L, Simon R (1986) The Norton–Simon hypothesis revisited. Cancer Treat Rep 70:41–61
40. Pasquier E, Ledzewicz U (2013) Perspective on ”More is not necessarily better”: metronomic chemotherapy. Newslett Soc Math Biol 26(2):9–10
41. Pasquier E, Kavallaris M, André N (2010) Metronomic chemotherapy: new rationale for new directions. Nat Rev Clin Oncol 7:455–465
42. Pietras K, Hanahan D (2005) A multi-targeted, metronomic and maximum tolerated dose ”chemo-switch” regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J Clin Oncol 23:939–952
43. Schättler H, Ledzewicz U, Cardwell B (2011) Robustness of optimal controls for a class of mathematical models for tumor anti-angiogenesis. Math Biosci Eng 8(2):355–369
44. Skipper HE (1986) On mathematical modeling of critical variables in cancer treatment (goals: better understanding of the past and better planning in the future). Bull Math Biol 48:253–278
45. Sole RV (2003) Phase transitions in unstable cancer cell populations. Eur J Phys B 35:117–124
46. Stepanova NV (1980) Course of the immune reaction during the development of a malignant tumour. Biophysics 24:917–923
47. Swann JB, Smyth MJ (2007) Immune surveillance of tumors. J Clin Investig 117:1137–1146
48. Weitman SD, Glatstein E, Kamen BA (1993) Back to the basics: the importance of concentration × time in oncology. J Clin Oncol 11:820–821
49. Wheldon TE (1988) Mathematical models in cancer research. Hilger Publishing, Boston
50. Whiteside TL (2008) The tumor microenvironment and its role in promoting tumor growth. Oncogene 27:5904–5912